Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis

Arthritis Research and Therapy

Volumn 14, Issue 1, 2012, Pages

  Zickert, Agneta ^a   Palmblad, Karin ^a   Sundelin, Birgitta ^a   Chavan, Sangeeta ^b   Tracey, Kevin J ^b   Bruchfeld, Annette ^a   Gunnarsson, Iva ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATININE; CYCLOPHOSPHAMIDE; HIGH MOBILITY GROUP B1 PROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE CLASSIFICATION; ERYTHROCYTE COUNT; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MESANGIUM; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEINURIA; WESTERN BLOTTING; ADOLESCENT; BIOPSY; BIOSYNTHESIS; BLOOD; KIDNEY; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADOLESCENT; ADULT; BIOPSY; BLOTTING, WESTERN; FEMALE; HMGB1 PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; LUPUS NEPHRITIS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84857133496     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3747     Document Type: Article

References (40)

1. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008, 358:929-939. 10.1056/NEJMra071297, 18305268.
2. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Mejia JC, Aydintug AO, Chwalinska-Sadowska H, de Ramon E, Fernández-Nebro A, Galeazzi M, Valen M, Mathieu A, Houssiau F, Caro N, Alba P, Ramos-Casals M, Ingelmo M, Hughes GR, . European Working Party on Systemic Lupus Erythematosus Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003, 82:299-308. European Working Party on Systemic Lupus Erythematosus.
3. Bianchi ME, Beltrame M, Paonessa G. Specific recognition of cruciform DNA by nuclear protein HMG1. Science 1989, 243:1056-1059. 10.1126/science.2922595, 2922595.
4. Muller S, Ronfani L, Bianchi ME. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med 2004, 255:332-343. 10.1111/j.1365-2796.2003.01296.x, 14871457.
5. Voll RE, Urbonaviciute V, Furnrohr B, Herrmann M, Kalden JR. The role of high-mobility group box 1 protein in the pathogenesis of autoimmune diseases. Curr Rheumatol Rep 2008, 10:341-342. 10.1007/s11926-008-0054-1, 18817635.
6. Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ. HMGB1 as a DNA-binding cytokine. J Leukoc Biol 2002, 72:1084-1091.
7. Pisetsky DS, Erlandsson-Harris H, Andersson U. High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther 2008, 10:209. 10.1186/ar2440, 2483460, 18598385.
8. Andersson U, Harris HE. The role of HMGB1 in the pathogenesis of rheumatic disease. Biochim Biophys Acta 2010, 1799:141-148.
9. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195. 10.1038/nature00858, 12110890.
10. Wang H, Yang H, Tracey KJ. Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 2004, 255:320-331. 10.1111/j.1365-2796.2003.01302.x, 14871456.
11. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang M, Yang H, Tracey KJ. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000, 192:565-570. 10.1084/jem.192.4.565, 2193240, 10952726.
12. Treutiger CJ, Mullins GE, Johansson AS, Rouhiainen A, Rauvala HM, Erlandsson-Harris H, Andersson U, Yang H, Tracey KJ, Andersson J, Palmblad JE. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med 2003, 254:375-385. 10.1046/j.1365-2796.2003.01204.x, 12974876.
13. Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A, Rauvala H, Herman G, Tracey KJ, Lee ML, Andersson J, Tokics L, Treutiger CJ. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 2005, 33:564-573. 10.1097/01.CCM.0000155991.88802.4D, 15753748.
14. Kokkola R, Sundberg E, Ulfgren AK, Palmblad K, Li J, Wang H, Ulloa L, Yang H, Yan XJ, Furie R, Chiorazzi N, Tracey KJ, Andersson U, Harris HE. High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum 2002, 46:2598-2603. 10.1002/art.10540, 12384917.
15. Goldstein RS, Bruchfeld A, Yang L, Qureshi AR, Gallowitsch-Puerta M, Patel NB, Huston BJ, Chavan S, Rosas-Ballina M, Gregersen PK, Czura CJ, Sloan RP, Sama AE, Tracey KJ. Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis. Mol Med 2007, 13:210-215. 1899837, 17597834.
16. Bruchfeld A, Wendt M, Bratt J, Qureshi AR, Chavan S, Tracey KJ, Palmblad K, Gunnarsson I. High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations. Mol Med 2011, 17:29-35. 3022976, 20844833.
17. Bruchfeld A, Qureshi AR, Lindholm B, Barany P, Yang L, Stenvinkel P, Tracey KJ. High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD). Mol Med 2008, 14:109-115. 10.1007/s00894-007-0256-x, 2258159, 18317568.
18. Urbonaviciute V, Furnrohr BG, Weber C, Haslbeck M, Wilhelm S, Herrmann M, Voll RE. Factors masking HMGB1 in human serum and plasma. J Leukoc Biol 2007, 81:67-74.
19. Jiang W, Pisetsky DS. Expression of high mobility group protein 1 in the sera of patients and mice with systemic lupus erythematosus. Ann Rheum Dis 2008, 67:727-728.
20. Li J, Xie H, Wen T, Liu H, Zhu W, Chen X. Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus. J Rheumatol 2010, 37:766-775. 10.3899/jrheum.090663, 20110525.
21. Barkauskaite V, Ek M, Popovic K, Harris HE, Wahren-Herlenius M, Nyberg F. Translocation of the novel cytokine HMGB1 to the cytoplasm and extracellular space coincides with the peak of clinical activity in experimentally UV-induced lesions of cutaneous lupus erythematosus. Lupus 2007, 16:794-802. 10.1177/0961203307081895, 17895302.
22. Abdulahad DA, Westra J, Bijzet J, Limburg PC, Kallenberg CG, Bijl M. High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther 2011, 13:R71. 10.1186/ar3332, 3218880, 21548924.
23. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277. 10.1002/art.1780251101, 7138600.
24. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
25. Churg J, Bernstein J, Glassock RJ. Renal Disease: Classification and Atlas of Glomerular Diseases 1995, New York, Tokyo: Igakuso Shoin, 2.
26. Austin HA, Muenz LR, Joyce KM, Antonovych TA, Kullick ME, Klippel JH, Decker JL, Balow JE. Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 1983, 75:382-391. 10.1016/0002-9343(83)90338-8, 6351607.
27. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, Symmons DP, Viner N, Zoma A. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993, 86:447-458.
28. Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, D'Cruz D, Griffiths B, Khamashta M, Maddison P McHugh N, Snaith M, The LS, Yee CS, Zoma A, Gordon C. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005, 44:902-906.
29. Yee CS, Farewell V, Isenberg DA, Griffiths B, Teh LS, Bruce IN, Ahmad Y, Rahman A, Prabu A, Akil M, McHugh N, Edwards C, D'Cruz D, Khamashta MA, Maddison P, Gordon C. The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology (Oxford) 2009, 48:691-695.
30. Gunnarsson I, Sundelin B, Heimburger M, Forslid J, van Vollenhoven R, Lundberg I, Jacobson SH. Repeated renal biopsy in proliferative lupus nephritis--predictive role of serum C1q and albuminuria. J Rheumatol 2002, 29:693-699.
31. Hill GS, Delahousse M, Nochy D, Remy P, Mignon F, Mery JP, Bariety J. Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int 2001, 59:304-316.
32. Najafi CC, Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 2001, 59:2156-2163.
33. Janko C, Schorn C, Grossmayer GE, Frey B, Herrmann M, Gaipl US, Munoz LE. Inflammatory clearance of apoptotic remnants in systemic lupus erythematosus (SLE). Autoimmun Rev 2008, 8:9-12. 10.1016/j.autrev.2008.07.015, 18703173.
34. Bell CW, Jiang W, Reich CF, Pisetsky DS. The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 2006, 291:C1318-1325. 10.1152/ajpcell.00616.2005, 16855214.
35. Kruse K, Janko C, Urbonaviciute V, Mierke CT, Winkler TH, Voll RE, Schett G, Munoz LE, Herrmann M. Inefficient clearance of dying cells in patients with SLE: anti-dsDNA autoantibodies, MFG-E8, HMGB-1 and other players. Apoptosis 2010, 15:1098-1113. 10.1007/s10495-010-0478-8, 20198437.
36. Urbonaviciute V, Furnrohr BG, Meister S, Munoz L, Heyder P, De Marchis F, Bianchi ME, Kirschning C, Wagner H, Manfredi AA, Kalden JR, Schett G, Rovere-Querini P, Herrmann M, Voll RE. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 2008, 205:3007-3018. 10.1084/jem.20081165, 2605236, 19064698.
37. Hayashi A, Nagafuchi H, Ito I, Hirota K, Yoshida M, Ozaki S. Lupus antibodies to the HMGB1 chromosomal protein: epitope mapping and association with disease activity. Mod Rheumatol 2009, 19:283-292. 10.1007/s10165-009-0151-7, 19214652.
38. Christopher-Stine L, Siedner M, Lin J, Haas M, Parekh H, Petri M, Fine DM. Renal biopsy in lupus patients with low levels of proteinuria. J Rheumatol 2007, 34:332-335.
39. Gordon C, Jayne D, Pusey C, Adu D, Amoura Z, Aringer M, Ballerin J, Cervera R, Calvo-Alén J, Chizzolini C, Dayer J, Doria A, Ferrario F, Floege J, Guillevin L, Haubitz M, Hiepe F, Houssiau F, Lesavre P, Lightstone L, Meroni P, Meyer O, Moulin B, O'Reilly K, Praga M, Schulze-Koops H, Sinico R, Smith K, Tincani A, Vasconcelos C, et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus 2009, 18:257-263. 10.1177/0961203308100481, 19213865.
40. Yang H, Tracey KJ. Targeting HMGB1 in inflammation. Biochim Biophys Acta 2010, 1799:149-156.